)
Visual
earnings real time
Viridian Therapeutics (VRDN) investor relations material
Viridian Therapeutics Evercore ISI 8th Annual HealthCONx Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Evercore ISI 8th Annual HealthCONx Conference summary4 Dec, 2025
Key clinical program updates
Achieved strong results across proptosis, diplopia, and clinical activity score endpoints, leading to Breakthrough Therapy Designation submission.
Rapid treatment effect observed after one infusion, with majority of patients responding within three weeks.
Subcutaneous program uses the same antibody as IV, with half-life extension for at-home self-administration; top-line data expected in Q1 and Q2 for active and chronic populations.
Both IV and subcutaneous programs target a $2B U.S. market, with plans for European MAA filing in Q1 and recent partnership in Japan.
Placebo response rates have been consistently low in large studies, with robust operational consistency across trials.
Product differentiation and market strategy
Subcutaneous formulation offers at-home administration via auto-injector, increasing patient convenience and access.
Treatment regimen is shorter (three months, five infusions) and uses 70% less drug compared to the current standard.
No need to switch patients from existing products; new option available at all stages post-diagnosis.
Commercial strategy leverages pricing insights from existing products in Europe and Japan.
Focus on validated targets and differentiated profiles in large markets, with additional FcRn programs in development.
Clinical trial design and expectations
REVEAL-1 (active) and REVEAL-2 (chronic) studies mirror successful THRIVE designs, enrolling broad and representative patient populations.
Subcutaneous 003 is de-risked, matching or exceeding IV exposure levels; efficacy bar set by TEPEZZA's 50%-70% placebo-adjusted proptosis response.
Placebo arms expected to remain low based on prior trial consistency; operational rigor maintained across studies.
Safety profile for IGF-1R is well known and manageable; subcutaneous formulation may offer improved safety due to lower Cmax and overall exposure.
Launch of veligrotug anticipated next year, with subcutaneous version following closely; no specific launch guidance provided yet.
Subcu safety profile vs. IV, given lower PK
Protocol features ensuring low placebo response
Commercial strategy for IV vs. subcu launch
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Viridian Therapeutics earnings date
Q4 202527 Feb, 2026
Next Viridian Therapeutics earnings date
Q4 202527 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
Viridian Therapeutics Inc. is a biotechnology company focused on developing treatments for patients with serious diseases, particularly those related to rare and underserved conditions. The company’s primary area of research includes therapies for thyroid eye disease (TED) and other autoimmune and inflammatory diseases. Viridian Therapeutics employs innovative biologics and small-molecule technologies to address unmet medical needs and improve patient outcomes through targeted therapeutic approaches. The company is headquartered in Waltham, Massachusetts, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage